Skip to content

Uncategorised

LumiThera Inc. have announced a multi-centre registry (“EUROLIGHT”) for their photo-biomodulation (PBM) treatment of dry AMD across up to 20 European centres.

A US company, LumiThera Inc., based in Seattle, WA, has announced a multi-centre clinical registry study to enroll up to 1,000 AMD patients with their… Read More »LumiThera Inc. have announced a multi-centre registry (“EUROLIGHT”) for their photo-biomodulation (PBM) treatment of dry AMD across up to 20 European centres.

The EMA Committee for Orphan Medicinal Products (COMP) propose a new approach to Orphan Designations (OD) on inherited retinal degenerations (IRDs).

A review from the Committee for Orphan Medicinal Products (COMP) at the European Medicines Agency (EMA) has reported that “orphan designations” (OD) on inherited retinal… Read More »The EMA Committee for Orphan Medicinal Products (COMP) propose a new approach to Orphan Designations (OD) on inherited retinal degenerations (IRDs).

Mutations, analysis and genotype-phenotype results from the largest cohort of Best disease patients in the Israeli population and worldwide.

Researchers at the Department of Ophthalmology, at The Hebrew University of Jerusalem, have reported a new comprehensive analysis on Best disease patients, aimed to document… Read More »Mutations, analysis and genotype-phenotype results from the largest cohort of Best disease patients in the Israeli population and worldwide.